Literature DB >> 8101523

Optimal versus maximally tolerated dose in cancer chemotherapy treatment.

M Markman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8101523     DOI： 10.1007/bf01372720

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  13 in total

1.  Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells.

Authors:  J Crown; C Wassherheit; T Hakes; D Fennelly; L Reich; M Moore; J Schneider; J Curtin; S C Rubin; B Reichman
Journal:  J Natl Cancer Inst       Date:  1992-12-16       Impact factor: 13.506

Review 2.  Hemopoietic growth factors: a review.

Authors:  G Morstyn; A W Burgess
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

3.  Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

Authors:  F A Holmes; R S Walters; R L Theriault; A D Forman; L K Newton; M N Raber; A U Buzdar; D K Frye; G N Hortobagyi
Journal:  J Natl Cancer Inst       Date:  1991-12-18       Impact factor: 13.506

4.  Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.

Authors:  A I Einzig; P H Wiernik; J Sasloff; C D Runowicz; G L Goldberg
Journal:  J Clin Oncol       Date:  1992-11       Impact factor: 44.544

5.  Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.

Authors:  A Y Chang; K Kim; J Glick; T Anderson; D Karp; D Johnson
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

6.  Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.

Authors:  W K Murphy; F V Fossella; R J Winn; D M Shin; H E Hynes; H M Gross; E Davilla; J Leimert; H Dhingra; M N Raber
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

7.  Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.

Authors:  G Sarosy; E Kohn; D A Stone; M Rothenberg; J Jacob; D O Adamo; F P Ognibene; R E Cunnion; E Reed
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

8.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.

Authors:  S J Brandt; W P Peters; S K Atwater; J Kurtzberg; M J Borowitz; R B Jones; E J Shpall; R C Bast; C J Gilbert; D H Oette
Journal:  N Engl J Med       Date:  1988-04-07       Impact factor: 91.245

Review 9.  Taxol: a novel investigational antimicrotubule agent.

Authors:  E K Rowinsky; L A Cazenave; R C Donehower
Journal:  J Natl Cancer Inst       Date:  1990-08-01       Impact factor: 13.506

10.  A phase II trial of taxol in metastatic melanoma.

Authors:  S S Legha; S Ring; N Papadopoulos; M Raber; R S Benjamin
Journal:  Cancer       Date:  1990-06-01       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.